Sanofi(US:SNY) Globenewswire·2026-02-16 06:00Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate among 11,796 infants out of 12,492 eligible, with an 85.9% reduction in RSV-related lower respiratory tract infection hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in lower respiratory tract infection rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health, influencing infant immunization strategies and economic evaluation models [3][4] - The study's results provide compelling population-based data that can inform public health policies regarding RSV immunization [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions that make them vulnerable to RSV disease [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose to newborns and infants [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries, demonstrating its widespread acceptance and use [11]